Glasdegib
- Generic Name
- Glasdegib
- Brand Names
- Daurismo
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22N6O
- CAS Number
- 1095173-27-5
- Unique Ingredient Identifier
- K673DMO5H9
- Background
Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group...
- Indication
Glasdegib, in combination with cytarabine, is indicated for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are over 75 years old or that have co-morbidities that preclude intensive induction chemotherapy.
...
- Associated Conditions
- Acute Myeloid Leukemia
- Associated Therapies
- -
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 75
- Registration Number
- NCT03226418
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation
- Conditions
- Interventions
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT03130556
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT02430545
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.